Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida(Aichi Cancer Center), Hiroshi Nokihara, Masashi Kondo(Nagoya University), Young Hak Kim(Kyoto University), Koichi Azuma(Kurume University), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Yuichi Takiguchi(Chiba University), Makoto Nishio(The Cancer Institute Hospital), Hiroshige Yoshioka(Kurashiki Central Hospital), Fumio Imamura(Osaka Medical Center for Cancer and Cardiovascular Diseases), Katsuyuki Hotta(Okayama University Hospital), Satoshi Watanabe(Niigata University), Kōichi Goto(National Cancer Center Hospital East), Miyako Satouchi(Hyogo Prefectural Cancer Center), Toshiyuki Kozuki(Shikoku Cancer Center), Takehito Shukuya(Juntendo University), Kazuhiko Nakagawa(Kindai University), Tetsuya Mitsudomi(Kindai University), Nobuyuki Yamamoto(Wakayama Medical University), T. Asakawa, Ryoichi Asabe, Tomohiro Tanaka, Tomohide Tamura(St. Luke's International Hospital)
The Lancet
May 11, 2017
Cited by 909

Abstract


Related Papers

No related papers found

Powered by citation graph analysis